The role of EGFR-met interactions in the pathogenesis of glioblastoma and resistance to treatment

Gao Guo, Ram N. Narayan, Lindsay Horton, Toral R. Patel, Amyn A. Habib

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. It is a devastating and intractable disease with a poor outcome. Aberrant receptor tyrosine kinase signaling is a key driver in gliomagenesis and resistance to treatment. EGFR gene amplification and mutations are an important genetic alteration in GBM resulting in increased expression of EGFR wild type (EGFRwt) as well as mutant oncogenic forms of the EGFR. EGFRvIII is the most common oncogenic mutant in GBM and is usually co-expressed with EGFRwt. EGFRvIII does not bind ligand and is constitutively active. Recent studies have also highlighted a key role for Met in gliomagenesis and the EGFR and Met may act in concert to promote the malignant phenotype. Met is transactivated by EGFRvIII and plays a key role in EGFRvIII-mediated resistance to targeted treatment. HGF, a Met ligand, is highly expressed in GBM. HGF and Met create an important autocrine signaling loop that promotes GBM invasion. In addition, HGF/Met is able to induce EGFR activation, leading to enhanced activation of oncogenic signaling in GBM. In this review, we discuss the evidence for EGFR and Met interaction in GBM and discuss the mechanisms and biological consequences of transactivation between the two kinases. Additionally, we discuss the therapeutic potential of targeting both EGFR and Met signaling for the treatment of GBM.

Original languageEnglish (US)
Pages (from-to)297-302
Number of pages6
JournalCurrent Cancer Drug Targets
Volume17
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Glioblastoma
Autocrine Communication
Ligands
erbB-1 Genes
Gene Amplification
Receptor Protein-Tyrosine Kinases
Brain Neoplasms
Transcriptional Activation
Phosphotransferases
Phenotype
Mutation
epidermal growth factor receptor VIII

Keywords

  • Antagonistic. EGFR wild type
  • EGFR
  • EGFR mutants
  • EGFRvIII
  • GBM
  • Glioblastoma
  • Glioma
  • Met
  • Synergistic
  • Targeted treatment

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Cancer Research

Cite this

The role of EGFR-met interactions in the pathogenesis of glioblastoma and resistance to treatment. / Guo, Gao; Narayan, Ram N.; Horton, Lindsay; Patel, Toral R.; Habib, Amyn A.

In: Current Cancer Drug Targets, Vol. 17, No. 3, 01.03.2017, p. 297-302.

Research output: Contribution to journalReview article

@article{83be436473b6476eac15418a8580cbed,
title = "The role of EGFR-met interactions in the pathogenesis of glioblastoma and resistance to treatment",
abstract = "Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. It is a devastating and intractable disease with a poor outcome. Aberrant receptor tyrosine kinase signaling is a key driver in gliomagenesis and resistance to treatment. EGFR gene amplification and mutations are an important genetic alteration in GBM resulting in increased expression of EGFR wild type (EGFRwt) as well as mutant oncogenic forms of the EGFR. EGFRvIII is the most common oncogenic mutant in GBM and is usually co-expressed with EGFRwt. EGFRvIII does not bind ligand and is constitutively active. Recent studies have also highlighted a key role for Met in gliomagenesis and the EGFR and Met may act in concert to promote the malignant phenotype. Met is transactivated by EGFRvIII and plays a key role in EGFRvIII-mediated resistance to targeted treatment. HGF, a Met ligand, is highly expressed in GBM. HGF and Met create an important autocrine signaling loop that promotes GBM invasion. In addition, HGF/Met is able to induce EGFR activation, leading to enhanced activation of oncogenic signaling in GBM. In this review, we discuss the evidence for EGFR and Met interaction in GBM and discuss the mechanisms and biological consequences of transactivation between the two kinases. Additionally, we discuss the therapeutic potential of targeting both EGFR and Met signaling for the treatment of GBM.",
keywords = "Antagonistic. EGFR wild type, EGFR, EGFR mutants, EGFRvIII, GBM, Glioblastoma, Glioma, Met, Synergistic, Targeted treatment",
author = "Gao Guo and Narayan, {Ram N.} and Lindsay Horton and Patel, {Toral R.} and Habib, {Amyn A.}",
year = "2017",
month = "3",
day = "1",
doi = "10.2174/1568009616666161215162515",
language = "English (US)",
volume = "17",
pages = "297--302",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - The role of EGFR-met interactions in the pathogenesis of glioblastoma and resistance to treatment

AU - Guo, Gao

AU - Narayan, Ram N.

AU - Horton, Lindsay

AU - Patel, Toral R.

AU - Habib, Amyn A.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. It is a devastating and intractable disease with a poor outcome. Aberrant receptor tyrosine kinase signaling is a key driver in gliomagenesis and resistance to treatment. EGFR gene amplification and mutations are an important genetic alteration in GBM resulting in increased expression of EGFR wild type (EGFRwt) as well as mutant oncogenic forms of the EGFR. EGFRvIII is the most common oncogenic mutant in GBM and is usually co-expressed with EGFRwt. EGFRvIII does not bind ligand and is constitutively active. Recent studies have also highlighted a key role for Met in gliomagenesis and the EGFR and Met may act in concert to promote the malignant phenotype. Met is transactivated by EGFRvIII and plays a key role in EGFRvIII-mediated resistance to targeted treatment. HGF, a Met ligand, is highly expressed in GBM. HGF and Met create an important autocrine signaling loop that promotes GBM invasion. In addition, HGF/Met is able to induce EGFR activation, leading to enhanced activation of oncogenic signaling in GBM. In this review, we discuss the evidence for EGFR and Met interaction in GBM and discuss the mechanisms and biological consequences of transactivation between the two kinases. Additionally, we discuss the therapeutic potential of targeting both EGFR and Met signaling for the treatment of GBM.

AB - Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. It is a devastating and intractable disease with a poor outcome. Aberrant receptor tyrosine kinase signaling is a key driver in gliomagenesis and resistance to treatment. EGFR gene amplification and mutations are an important genetic alteration in GBM resulting in increased expression of EGFR wild type (EGFRwt) as well as mutant oncogenic forms of the EGFR. EGFRvIII is the most common oncogenic mutant in GBM and is usually co-expressed with EGFRwt. EGFRvIII does not bind ligand and is constitutively active. Recent studies have also highlighted a key role for Met in gliomagenesis and the EGFR and Met may act in concert to promote the malignant phenotype. Met is transactivated by EGFRvIII and plays a key role in EGFRvIII-mediated resistance to targeted treatment. HGF, a Met ligand, is highly expressed in GBM. HGF and Met create an important autocrine signaling loop that promotes GBM invasion. In addition, HGF/Met is able to induce EGFR activation, leading to enhanced activation of oncogenic signaling in GBM. In this review, we discuss the evidence for EGFR and Met interaction in GBM and discuss the mechanisms and biological consequences of transactivation between the two kinases. Additionally, we discuss the therapeutic potential of targeting both EGFR and Met signaling for the treatment of GBM.

KW - Antagonistic. EGFR wild type

KW - EGFR

KW - EGFR mutants

KW - EGFRvIII

KW - GBM

KW - Glioblastoma

KW - Glioma

KW - Met

KW - Synergistic

KW - Targeted treatment

UR - http://www.scopus.com/inward/record.url?scp=85013947211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013947211&partnerID=8YFLogxK

U2 - 10.2174/1568009616666161215162515

DO - 10.2174/1568009616666161215162515

M3 - Review article

C2 - 28004613

AN - SCOPUS:85013947211

VL - 17

SP - 297

EP - 302

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 3

ER -